Close Menu

NEW YORK (GenomeWeb) – Qiagen said on Wednesday that it has entered into a licensing and co-development agreement with Germany's Therawis Diagnostics in the area of predictive assays in oncology.

An initial project under the agreement will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients. PITX2 encodes for a protein called paired-like homeodomain transcription factor 2, which acts as a transcriptional regulator in basal and hormone-regulated activity of prolactin.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Jun
26
Sponsored by
Lexogen

This webinar will outline a study that combined genome-wide and classical molecular approaches to demonstrate that translation strongly affects mRNA stability in a codon-dependent manner, ultimately influencing mRNA and protein levels in higher organisms.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.